General Information of Drug Therapeutic Target (DTT) (ID: TT2UE56)

DTT Name Sodium/glucose cotransporter 1 (SGLT1)
Synonyms Solute carrier family 5 member 1; Na(+)/glucose cotransporter 1; NAGT; High affinity sodium-glucose cotransporter
Gene Name SLC5A1
DTT Type
Clinical trial target
[1]
BioChemical Class
Solute:sodium symporter
UniProt ID
SC5A1_HUMAN
TTD ID
T54771
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MDSSTWSPKTTAVTRPVETHELIRNAADISIIVIYFVVVMAVGLWAMFSTNRGTVGGFFL
AGRSMVWWPIGASLFASNIGSGHFVGLAGTGAASGIAIGGFEWNALVLVVVLGWLFVPIY
IKAGVVTMPEYLRKRFGGQRIQVYLSLLSLLLYIFTKISADIFSGAIFINLALGLNLYLA
IFLLLAITALYTITGGLAAVIYTDTLQTVIMLVGSLILTGFAFHEVGGYDAFMEKYMKAI
PTIVSDGNTTFQEKCYTPRADSFHIFRDPLTGDLPWPGFIFGMSILTLWYWCTDQVIVQR
CLSAKNMSHVKGGCILCGYLKLMPMFIMVMPGMISRILYTEKIACVVPSECEKYCGTKVG
CTNIAYPTLVVELMPNGLRGLMLSVMLASLMSSLTSIFNSASTLFTMDIYAKVRKRASEK
ELMIAGRLFILVLIGISIAWVPIVQSAQSGQLFDYIQSITSYLGPPIAAVFLLAIFWKRV
NEPGAFWGLILGLLIGISRMITEFAYGTGSCMEPSNCPTIICGVHYLYFAIILFAISFIT
IVVISLLTKPIPDVHLYRLCWSLRNSKEERIDLDAEEENIQEGPKETIEIETQVPEKKKG
IFRRAYDLFCGLEQHGAPKMTEEEEKAMKMKMTDTSEKPLWRTVLNVNGIILVTVAVFCH
AYFA
Function
Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules. Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1.
KEGG Pathway
Carbohydrate digestion and absorption (hsa04973 )
Bile secretion (hsa04976 )
Mineral absorption (hsa04978 )
Reactome Pathway
Na+-dependent glucose transporters (R-HSA-428808 )
Inositol transporters (R-HSA-429593 )
Hexose transport (R-HSA-189200 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [1]
------------------------------------------------------------------------------------
5 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
LIK-066 DM32NWD Heart failure BD10-BD13 Phase 2 [2]
YG1699 DM1NR1J Type-1 diabetes 5A10 Phase 2 [3]
1614235 + 2330672 DMD751X Type-2 diabetes 5A11 Phase 1 [2]
GSK1614235 DM7I1AQ Type-2 diabetes 5A11 Phase 1 [4]
LX2761 DM8ZS7T Type 2 diabetes 5A11 Phase 1 [5]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
T-1095 DMGFS51 Diabetic complication 5A2Y Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------
18 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X Discovery agent N.A. Investigative [7]
Acerogenin A DM4BWMO Discovery agent N.A. Investigative [8]
ACEROGENIN B DMVQ30P Discovery agent N.A. Investigative [8]
Alstiphyllanine D DM2FLDJ Discovery agent N.A. Investigative [7]
Alstiphyllanine E DMTNQ5E Discovery agent N.A. Investigative [7]
Alstiphyllanine F DMKRAEW Discovery agent N.A. Investigative [7]
Burnamine-17-O-3',4',5'-trimethoxybenzoate DMBO0WI Discovery agent N.A. Investigative [7]
KURAIDIN DMLDUJ1 Discovery agent N.A. Investigative [9]
KURARINONE DMH0G8W Discovery agent N.A. Investigative [9]
Kushenol N DMY13UR Discovery agent N.A. Investigative [9]
O-spiroketal glucoside DM3FS62 Discovery agent N.A. Investigative [10]
Phlorizin DMNARGO Discovery agent N.A. Investigative [11]
QCP DM62PI8 Discovery agent N.A. Investigative [12]
QCPac DMSMQXZ Discovery agent N.A. Investigative [12]
QNEQCPQVSac DMTY5HP Discovery agent N.A. Investigative [12]
QSPac DMJHTUG Discovery agent N.A. Investigative [12]
sergliflozin DMF8GAX Discovery agent N.A. Investigative [13]
Sophoraflavanone G DMBTMN5 Discovery agent N.A. Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Type 2 diabetes 5A11 Liver tissue 9.67E-01 0.08 0.42
------------------------------------------------------------------------------------

The Drug Transporter (DTP) Role of This DTT

DTT DTP Name Sodium/glucose cotransporter 1 (SLC5A1) DTP Info
Gene Name SLC5A1
1 Approved Drug(s) Transported by This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [14]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Transported by This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fucose DMAHMSV N. A. N. A. Investigative [14]
------------------------------------------------------------------------------------

References

1 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
3 ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
6 T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
7 Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
8 Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
9 Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
10 ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.
11 J Biol Chem. 1988 Jan 5;263(1):187-92.High affinity phlorizin binding to the LLC-PK1 cells exhibits a sodium:phlorizin stoichiometry of 2:1.
12 Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13.
13 Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal gluco... J Pharmacol Exp Ther. 2007 Jan;320(1):323-30.
14 The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977.